ライフサイエンスコーパス: clinical cure

1 The outcome was resolution of disease (clinical "cure").

2 alized with bacterial pneumonia who achieved clinical cure.

3 d intentionally create mixed chimerism and a clinical cure.

4 ate well with response to treatment and with clinical cure.

5 of 400 mg of fluconazole were necessary for clinical cure.

6 ted for retreatment with quinacrine achieved clinical cure.

7 ells, facilitating immune-drug synergism and clinical cure.

8 uded intensive care unit (ICU) mortality and clinical cure.

9 Uterine microbiome was not associated with clinical cure.

10 235 (81%) of 290 versus 258 (86%) of 301 had clinical cure.

11 mination of the correlation of sputum LAM to clinical cure.

12 patients with bacterial pneumonia following clinical cure.

13 ration was not independently associated with clinical cure.

14 g hospital mortality censored at 30 days and clinical cure.

15 with mortality; however, it had no effect on clinical cure.

16 ermittent administration with improvement in clinical cure.

17 d treatment-related factors on mortality and clinical cure.

18 was recurrence during the 28 days following clinical cure.

19 et criteria for noninferiority for achieving clinical cure.

20 Secondary outcomes were 90-day survival, clinical cure 14 days post antibiotic cessation, alive o

21 The primary endpoint was sustained clinical cure 30 days after end of treatment (day 55 for

22 tended-pulsed fidaxomicin achieved sustained clinical cure 30 days after end of treatment, compared w

23 composite of microbiological eradication and clinical cure 5-9 days after treatment in the microbiolo

24 exafungerp had significantly higher rates of clinical cure (50.5% [95/188] vs 28.6% [28/98]; P = .001

25 The primary outcome was clinical cure 7 to 10 days after the end of treatment.

26 Secondary end points were clinical cure 7 to 14 days after the end of treatment, a

27 escue antibiotic); (2) investigator-assessed clinical cure 7-14 days after end of treatment; and (3)

28 Rates of clinical cure (73% vs 62.9%, P = .195) and rCDI (3.3% vs

29 .4 percentage points); investigator-assessed clinical cure, 79.6% versus 80.0% (95% CI for the differ

30 al [CI], -7.5 to 2.0), investigator-assessed clinical cure (82.7% vs 80.5%; 95% CI, -2.6 to 7.0), and

31 e of anaerobic organisms in the endometrium, clinical cure (absence of fever and reduction in tendern

32 ependent impact of ceftolozane/tazobactam on clinical cure, acute kidney injury (AKI), and in-hospita

33 tazobactam was independently associated with clinical cure (adjusted odds ratio [aOR], 2.63; 95% conf

34 All the patients were followed up for clinical cure after 10 days of treatment.

35 ost T cell-intact patients show long-lasting clinical cure after treatment despite residual intracell

36 ocyte and neutrophil activation characterize clinical cure after treatment of CL, supporting particip

37 Post hoc analysis showed similar rates of clinical cure and clinical improvement at test-of-cure f

38 d point was overall response (a composite of clinical cure and favorable microbiologic response) at a

39 The primary end points were composite cure (clinical cure and microbiologic eradication) at day 5 an

40 ority with respect to the primary outcome of clinical cure and microbiological eradication.

41 th mycological eradication, overall success (clinical cure and mycological eradication), clinical imp

42 Clinical cure and no disease recurrence within 60 days w

43 rences in uterine microbiome associated with clinical cure and pregnancy outcomes in dairy cows treat

44 Rates of initial clinical cure and rCDI were summarized by eAb titer cate

45 Clinical cure and recurrence outcomes were analyzed by s

46 Rates of both initial clinical cure and SCC at 28 days were 100% (10 of 10 pat

47 To understand the inconsistency between the clinical cure and the presence of "residual disease" at

48 ttent injection have failed to show superior clinical cures and for the most part microbiological suc

49 resent at study entry, with no new symptoms (clinical cure), and a reduction in density of the origin

50 The primary endpoint was clinical cure assessed at week 12 and included a composi

51 Clinical cure at 14 to 21 days was observed in 108 of 12

52 The efficacy outcomes included clinical cure at 24 hours and time to last unformed stoo

53 Clinical cure at 24 hours occurred in 81.4%, 78.3%, and

54 Clinical cure at day 14 and no recurrence with or withou

55 The primary outcome was clinical cure at day 7, which was assessed from diaries

56 The primary test of cure (TOC) was clinical cure at day 9-12; safety was assessed at TOC an

57 For the primary end point, clinical cure at days 6-10 post-end of treatment (PET),

58 The primary outcome measure was clinical cure at end of therapy visit (EOT) at Days 9 to

59 terms of both 28-day all-cause mortality and clinical cure at test of cure.

60 The primary end point was clinical cure at test-of-cure visit 28-35 days after ran

61 of a sustained clinical response, defined as clinical cure at the end of treatment and no recurrence

62 Rates of clinical cure at the last evaluation were similar among

63 The primary endpoint was clinical cure at the test-of-cure visit (21-25 days afte

64 The primary endpoint was clinical cure at the test-of-cure visit (8-15 days after

65 Clinical cure at the test-of-cure visit was observed in

66 cal intent-to-treat population, the rates of clinical cure at the test-of-cure visit were 86.8% in th

67 The overall proportions of patients with a clinical cure at the test-of-cure visit were similar wit

68 For each CMS course, clinical cure, bacteriological clearance, daily serum cr

69 obial treatment had no significant effect on clinical cure, bacteriological cure, pathogen clearance

70 cal ventilation-free days though day 28, and clinical cure between day 7 and day 10 after treatment i

71 entilation-free days through day 28, and (3) clinical cure between study days 7 and 10 for VABP; and

72 Clinical cure by day 7 occurred in 128 (83%) of 155 chil

73 a, and cancer were inversely associated with clinical cure by multivariate analysis.

74 daxomicin regimen might facilitate sustained clinical cure by prolonging C difficile suppression and

75 and follow-up visits and were classified as clinical cure, clinical failure, or indeterminate/missin

76 hieved overall treatment success (defined as clinical cure combined with microbiological eradication

77 logy of MABC was associated to lower odds of clinical cure compared to smooth morphology (adjusted od

78 ipants in the ibezapolstat group had initial clinical cure compared with 14 (100%) of 14 participants

79 ents (90.9%) in the donor FMT group achieved clinical cure compared with 15 of 24 (62.5%) in the auto

80 dpoint was the percentage of patients with a clinical cure (complete resolution of vulvovaginal signs

81 dpoint was the percentage of patients with a clinical cure (complete resolution of vulvovaginal signs

82 for VABP; and (1) survival (day 28) and (2) clinical cure (days 7-10) for HABP.

83 cteriaceae (CRE), leading to higher rates of clinical cure, decreased mortality, and decreased rates

84 mined a priori in the per-protocol group was clinical cure, defined as absence of these clinical fail

85 In pathogen-specific analyses, clinical cure did not differ by arm, nor did microbiolog

86 ve been shown to persist in their host after clinical cure, establishing the risk of disease reactiva

87 in MICs of baseline isolates did not predict clinical cure, failure, or recurrence of C. difficile in

88 The primary end point was clinical cure (firm stools or <3 bowel movements daily)

89 s the major obstacle to the development of a clinical cure for established HIV-1 infection.

90 The rates of hospital mortality and clinical cure for the continuous versus intermittent inf

91 Intravaginal cooling provides clinical cure for VVC and proof of principle in an anima

92 highly likely to increase the probability of clinical cure from infection and suppress the emergence

93 ondition occurring frequently after apparent clinical cure from visceral leishmaniasis.

94 ot IDO1 expression was predictive of rate of clinical cure (HR = 4.88) and occurred in parallel with

95 broad-spectrum Gram-negative coverage, with clinical cure in 69.7%.

96 terial community underlie fertility loss and clinical cure in cows with metritis.

97 247 (88%) of 282 versus 264 (92%) of 288 had clinical cure in IMPACT 1 and 214 (87%) of 247 versus 23

98 ndpoint of non-inferiority to vancomycin for clinical cure in one of two phase 3 C difficile infectio

99 ence demonstrated that the capsules produced clinical cure in patients with CDI with no adverse event

100 zolid is superior to vancomycin in achieving clinical cure in patients with nosocomial pneumonia.

101 population in IMPACT 1, 253 (84%) of 302 had clinical cure in the cadazolid group versus 271 (85%) of

102 gin -10%) of cadazolid versus vancomycin for clinical cure in the modified intention-to-treat and per

103 resent randomized clinical trial was time to clinical cure (in days); in the meta-analysis, the prima

104 th complete or partial cure of hypertension (clinical cure) in 12 participants (43% [24-61]).

105 ive predictive value (94.3%-100.0%) for late clinical cure, including among hospitalized patients.

106 defined as resolution of symptoms at week 6 (clinical cure, LGV-CC), with an additional supporting ne

107 Clinical cure (<5 PMNs/HPF with or without urethral symp

108 The primary efficacy endpoint was initial clinical cure maintained for at least 48 h after the end

109 growth of the index pathogen at the time of clinical cure (microbiologic failure) and those with pat

110 and clinical outcomes (all-cause mortality, clinical cure, microbiological cure, treatment failure,

111 Outcomes evaluated consisted of clinical cure, microbiological eradication, and side eff

112 e TOC visit, 18.0% were discordant failures (clinical cure/microbiological persistence), and 6.7% wer

113 In the per-protocol population, clinical cure occurred in 182 (83.5%) of 218 participant

114 the modified intention-to-treat population, clinical cure occurred in 189 (76.2%) of 248 participant

115 In the per-protocol population, clinical cure occurred in 487 of 524 participants (92.9%

116 The primary end point was clinical cure of CDI at end of treatment, and a secondar

117 reatment with meglumine antimoniate (MA) and clinical cure of human CL caused by Leishmania (Viannia)

118 the modified intention-to-treat population, clinical cure of the abscess occurred in 507 of 630 part

119 The primary outcome was clinical cure of the abscess, assessed 7 to 14 days afte

120 of post-treatment specimens does not predict clinical cure or relapse.

121 , 70%-82%) receiving doxycycline experienced clinical cure (P = .40).

122 ry endpoints were global cure (consisting of clinical cure, radiological cure, and mycological eradic

123 FA score values ( p = 0.11), a higher day 14 clinical cure rate (overall, 43.7%), or a shorter MV dur

124 Failure Assessment (SOFA) score values, the clinical cure rate at day 14, and the time to mechanical

125 The clinical cure rate at test-of-cure for hospital-acquired

126 The overall clinical cure rate at the 30-day visit with the intent-t

127 The primary efficacy variable was clinical cure rate at the test-of-cure visit (days 25-50

128 There were no differences in initial clinical cure rate between BI and non-BI strains in eith

129 Clinical cure rate of BV at TOC was 59% (95% confidence

130 The clinical cure rate of patients infected with the epidemi

131 rimethoprim-sulfamethoxazole yields a higher clinical cure rate of uncomplicated cellulitis than ceph

132 ed as having not responded to treatment, the clinical cure rate was 83% (124/150) for ciprofloxacin c

133 The clinical cure rate was 85% after the treatment.

134 et if the lower 95% CI for the difference in clinical cure rate was less than 15 percentage points at

135 The clinical cure rate with ceftazidime-avibactam plus metro

136 resolution of organ failure, a higher day 14 clinical cure rate, or a shorter time to MV weaning or I

137 993 isolates, with a concomitant drop in the clinical cure rate.

138 ution MICs, E-test MICs, disc diffusion, and clinical cure rate.

139 The primary objectives were to assess clinical cure rates and adverse events (AEs).

140 Clinical cure rates at test of cure (TOC, day 19-21) wer

141 Clinical cure rates at test-of-cure were 80% (146 of 183

142 to demonstrate statistical noninferiority in clinical cure rates at the test-of-cure visit (24-32 day

143 monstrate statistical noninferiority (NI) in clinical cure rates at the test-of-cure visit (25-31 day

144 The clinical cure rates at visit 1 were 64 of 69 (92.8%) for

145 entage points) in the absolute difference in clinical cure rates between dequalinium chloride and met

146 The difference in clinical cure rates between the groups was -0.80% (95% C

147 At day 10, the clinical cure rates for ibrexafungerp and fluconazole we

148 Neonatal clinical cure rates for moxifloxacin (day 4, 48%), cipro

149 ysis of the trials for CABP (FOCUS 1 and 2), clinical cure rates for the ceftaroline group were numer

150 Notably, the clinical cure rates in ME patients with methicillin-resi

151 Secondary endpoints included clinical cure rates in the modified ITT population (231/

152 Preliminary data suggest that clinical cure rates may be lower among women with uncomp

153 as associated with greater bacteriologic and clinical cure rates than a 14-day trimethoprim-sulfameth

154 sing results, including fidaxomicin (similar clinical cure rates to vancomycin, with lower recurrence

155 Clinical cure rates were 67% for lower UTI and 80% for u

156 67.2% (41/61) for CAS; investigator-assessed clinical cure rates were 69.7% (53/76), 80.4% (37/46), a

157 ents with ESBL-producing Enterobacteriaceae, clinical cure rates were 87.5% (14/16) and 84.6% (11/13)

158 ents with ESBL-producing Enterobacteriaceae, clinical cure rates were 95.8% (23/24) and 88.5% (23/26)

159 Clinical cure rates were 96% (109 of 113) for the ciprof

160 patients with CABP caused by S. pneumoniae, clinical cure rates were markedly higher in the ceftarol

161 so have less bacterial eradication and lower clinical cure rates when treated with TMP-SMX for an inf

162 Clinical cure rates with ceftazidime-avibactam plus metr

163 en and adults, 95% CIs were constructed from clinical cure rates.

164 zolid is compared with vancomycin only, then clinical cure relative risk is 1.00 (95% confidence inte

165 he linezolid vs. glycopeptide analysis shows clinical cure relative risk of 1.01 (95% confidence inte

166 ye drops significantly shortened the time to clinical cure relative to no intervention.

167 M-guided dosing was associated with improved clinical cure (relative risk, 1.17; 95% confidence inter

168 .70-0.97; high certainty) and an increase in clinical cure (risk ratio, 1.16; 95% credible interval,

169 robiome and bile acid effects, and sustained clinical cure (SCC) with ibezapolstat.

170 : death, bacterial cultures, and presumptive clinical cure score.

171 Continued bacteriologic and clinical cure, such that alternative antimicrobial drugs

172 es of recurrent pneumonia or death following clinical cure than patients with microbiologic cure, con

173 es of recurrent pneumonia or death following clinical cure than patients with microbiologic cure, con

174 ts for VABP and HABP, and on a definition of clinical cure that could be considered for use in future

175 no participants (n = 0/69) with a sustained clinical cure through 12 weeks following bezlotoxumab in

176 Secondary outcomes included clinical cure, time to apyrexia, length of hospital stay

177 Clinical cure, time to apyrexia, LOS, and the occurrence

178 Non-inferiority for clinical cure to vancomycin was shown in IMPACT 1 but no

179 Secondary outcomes were clinical cure up to 14 days after randomization; new acq

180 Clinical cure was 52.4% (111 of 212) and 49.5% (109 of 2

181 lost to follow-up were considered as having clinical cure was 93% (139/150) for ciprofloxacin compar

182 Clinical cure was achieved in all women.

183 Clinical cure was defined as resolution of diarrhea for

184 Clinical cure was defined as resolution of diarrhoea wit

185 Clinical cure was defined as the combination of resoluti

186 Clinical cure was higher in the continuous group (70% vs

187 Clinical cure was higher in the continuous vs intermitte

188 Clinical cure was observed in 101 of 114 children (88.6%

189 Clinical cure was observed in 23 cases (82.1%).

190 The time to clinical cure was significantly shorter in the moxifloxa

191 Microbiologic and clinical cure were evaluated using previously defined cr

192 Rates of initial clinical cure were similar across eAb titer categories.

193 Those treated with MIL monotherapy attained clinical cure with a gradual decrease in parasite load;

194 The number needed to treat for a clinical cure with ceftolozane/tazobactam was 5, and the

195 Endpoints were clinical cure within 14 days and severe clinical failure

196 Overall, 439 patients had clinical cure (WPR, 76.1%; 95% confidence interval (CI),